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Abstract
Background—Control of genital infections remains challenging in most regions. Despite 
advocacy by the World Health Organization (WHO) for syndromic case management, there are 
limited data on the syndromic approach, especially in HIV care settings. This study compared the 
syndromic approach against laboratory diagnosis among women in HIV care in Kenya.
Methods—A mobile team visited 39 large HIV care programs in Kenya and enrolled participants 
using population-proportionate sampling. Participants provided behavioral and clinical data with 
genital and blood specimens for lab testing.
Results—Among 1,063 women, 68.4% had been on antiretroviral therapy >1 year; 58.9% were 
using cotrimoxazole prophylaxis; 51 % had CD4+T-lymphocytes < 350 cells/mL. Most women 
(63.1%) reported at least one genital symptom. Clinical signs were found in 63% of women; and 
30.8% had an etiological diagnosis. Bacterial vaginosis (17.4%), vaginal candidiasis (10.6%) and 
trichomoniasis (10.5%) were the most common diagnoses. Using laboratory diagnoses as gold 
standard, sensitivity and positive predictive value of the syndromic diagnosis for vaginal discharge 
were 47.6% and 52.7%, respectively, indicating a substantial amount of overtreatment. A 
systematic physical examination increased by 9.3% the positive predictive value for genital ulcer 
disease.
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Conclusions—Women attending HIV care programs in Kenya have high rates of vaginal 
infections. Syndromic diagnosis was a poor predictor of those infections.
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Introduction
Each year an estimated 340 million new sexually transmitted infections (STIs) are diagnosed 
globally, with 75–85% in developing countries (1). STI control measures include the 
promotion of safe sexual behaviors, prompt STI diagnosis and systematic treatment and 
partner notification and treatment (2). Owing to a lack of equipment and trained laboratory 
staff in developing countries, and testing costs, the World Health Organization (WHO) 
recommends a syndromic approach to STI management (3). Syndromic approaches rely on 
uniform treatment strategies to cover all likely pathogens responsible for a variety of 
infections. These syndromes are defined by a combination of self-reported symptoms and 
signs detected on physical examination. The most common syndromes are urethral discharge 
(UD) in men, vaginal discharge (VD) and lower abdominal pain (LAP) in women and 
genital ulcer disease (GUD) in both sexes (3).
Because it is unknown whether syndromic management is an effective STI control 
intervention in African populations infected with HIV, we conducted a large study within 
HIV care and treatment programs in Kenya to: 1) quantify the prevalence of genital 
infections; 2) evaluate the performance of STI syndromic case management for VD and 
GUD in symptomatic women against laboratory diagnoses and; 3) weigh the utility of 
incorporating systematic clinical STI screening in these programs.
Methods
Patient sampling and procedures
Probability proportional to size (PPS) sampling was used to select a random sample of 1,063 
women. Sampling and procedures for this study have been previously described by Singa et 
al. (4). Sociodemographic, sexual risk behaviors data and HIV/medical history were 
collected. Current STI symptoms were assessed and a genital examination with bimanual 
pelvic examination was performed. Blood, urine and genital specimens were systematically 
collected for laboratory testing. Participants diagnosed with a genital infection were 
provided immediate treatment. Asymptomatic patients diagnosed etiologically with 
laboratory confirmation were contacted to receive treatment. A referral card was provided 
for partner (s) to seek STI care and HIV testing. The study was approved by the institutional 
review boards of the U.S. Centers for Disease Control and Prevention, the University of 
Washington, and the Kenya Medical Research Institute.
Clinical definitions
A brief questionnaire on genital symptoms was administered and a physical examination 
was performed. The Kenyan syndromic diagnosis (KSD) was established on self-reported 
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symptoms and then genital examination. To assess whether systematic physical examination 
provided incremental STI diagnosis in the absence of symptoms, we defined the study 
clinician diagnosis (SCD) as any findings at systematic genital examination irrespective of 
symptom reporting. A VD syndrome was defined as self-reported vaginal discharge and the 
presence of profuse and/or mucopurulent or white, mucoid, yellowish-green vaginal 
discharge and/or the presence of discharge only at the time of examination. A GUD 
syndrome was defined as self-reported vesicles, ulcers and/or wounds in the genital, perineal 
and/or buttocks area and/or signs of genital ulcers at the time of examination.
Laboratory
Testing was performed for chlamydia, gonorrhea, trichomoniasis, syphilis, herpes simplex 
virus types 1 and 2 (HSV-1, HSV-2), bacterial vaginosis (BV) and vulvovaginal candidiasis 
(VVC). Vaginal swabs were collected from women during pelvic exam; a genital ulcer 
specimen was collected using a Dacron swab for genital ulcers. All participants had blood 
drawn to measure CD4 T-cell counts and for syphilis serology. A urine sample was collected 
for pregnancy testing.
Vaginal swab specimens were tested for Chlamydia trachomatis, Neisseria gonorrhoeae and 
Trichomonas vaginalis by transcription-mediated amplification (TMA) using the Gen-Probe 
APTIMA Combo 2GC/CT system (Hologic Gen-Probe, Inc., San Diego, CA). A positive 
TMA test for C. trachomatis, N. gonorrhoeae or T. vaginalis defined chlamydial, 
gonorrheal, or trichomoniasis infection, respectively. Syphilis testing was performed using 
rapid plasma reagin (RPR) assays for screening and Treponema pallidum haemagglutination 
assays (TPHA) for confirmation. Participants with positive RPR and TPHA were reported as 
having latent syphilis, in the absence of signs suggestive of active syphilis (5). Microscopy 
was used to examine Gram stained vaginal smear slides for Candida albicans and to 
evaluate for BV using Nugent’s scoring system (6). Scores of 0–3 represented normal 
vaginal flora, scores from 4–6 represented abnormal flora, and scores from 7–10 were 
classified as BV. Vulvovaginal candidiasis was defined as the presence of budding yeast or 
pseudohyphae on Gram stained vaginal swab smear along with self-reported genital itching 
and/or VD on exam. CD4 counts were assessed using FACSCalibur equipment (BD 
Biosciences, San Jose, CA). A real time multi-plex PCR test was used to detect HSV-1, 
HSV-2, Hemophilus ducreyi and Treponema pallidum from genital ulcers swabs.
Statistical analysis
Study enrollment site and sampling weight were included in the data analysis, which was 
conducted using SAS (Version 9.2, SAS Institute, Cary, NC, USA). Sampling weight was 
derived from the total number of patients on ART at each site, the number of patients 
sampled for recruitment at each site, and the number of patients ultimately enrolled. Tables 
and text present un-weighed sample size and weighed estimates with corresponding 95% 
confidence intervals (CIs).
The number of women who reported symptoms, who had at least one sign on physical 
examination, and who had asymptomatic genital infections were calculated separately. 
Asymptomatic infection was defined as women reporting no symptoms and had no signs on 
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physical examination, but had at least one positive laboratory result. Sensitivity, specificity, 
negative and positive predictive values and corresponding 95% CIs were calculated 
respectively for the KSD and the SCD. Microbiological diagnosis was used as gold standard 
in the above calculation for VD and GUD.
Results
One thousand and sixty-three women were enrolled. The median age was 36 years [range 
18–70] (Table 1). Approximately 46.5% were married and 55.6% had a primary education 
level. More than a third (44.3%) had not been sexually active three months prior to 
enrollment, while 53.8% and 1.9% reported one sex partner and more than one sex partner, 
respectively. Overall, 64.4% of sexually active women reported condom use at last sex. 
Twenty-two percent had been diagnosed with HIV within the past year, 68.4% had been on 
ART for more than 12 months, and 58.9% were on cotrimoxazole prophylaxis for 
opportunistic infections during the study.
Symptoms and signs
Overall, 63.1% of women reported at least one STI symptom, with VD as the most common, 
and 36.9% of women did not complain of any symptoms. Signs on examination were 
observed in 63.0% of women. Vulvovaginal discharge was observed in 66.2% (95%CI; 
57.6–74.8) of women reporting symptoms of VD (Table 2). Table 2 shows the most 
common diagnoses for women with signs of VD and GUD. All women presenting with 
signs at the physical examination were treated according to the syndromic management 
algorithms from the Kenyan ministry of health, regardless of the presence of symptoms.
Etiologic diagnosis and performance of syndromic management
Overall, 30.8% of women had a single diagnosis and 6.4% had mixed etiological diagnosis 
of genital infections. Bacterial infections such as gonorrhea and chlamydia accounted for 
1.6% and 0.5% of all diagnoses, respectively, and were never found together. The most 
common diagnoses were vaginal infections, including BV (17.4%), VVC (10.6%), and 
trichomoniasis (10.5%). Diagnoses stratified by cotrimoxazole prophylaxis were not 
statistically different (OR=0.94; 95%CI 0.66–1.35).
Table 3 summarizes the sensitivity, specificity, and positive and negative predictive values 
of the KSD and SCD using laboratory diagnosis as the gold standard for symptomatic 
women with VD and GUD syndromes. The sensitivity and positive predictive value of KSD 
for VD were estimated at 31.5% and 47.6%, respectively. Among symptomatic women with 
a KSD, 47.6% also had a laboratory diagnosis. The specificity was 78.1%, showing that 
approximately 22% of infections were misclassified. SCD yielded a sensitivity and positive 
predictive value of 34.3% and 49.1% respectively.
For GUD, KSD and SCD had a sensitivity of 77.6% and 89.1%, respectively; and a positive 
predictive value of 55.4% and 64.7%, respectively. Both yielded a relatively high 
specificity, as well as negative predictive value estimated above 99%. In summary, KSD for 
VD showed that 52.4% of women with a syndromic diagnosis did not have a positive 
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laboratory result. A SCD of GUD was a better predictor, by 9.3%, of a positive laboratory 
result.
Discussion
This etiologic study described genital infections among women in HIV care in Kenya. 
Overall, most women reported symptoms consistent with vaginal infections. Approximately 
17.4% of women had laboratory-confirmed BV, 10.5% candidiasis and 10.6% 
trichomoniasis. Because syndromic management relies on self-reported symptoms and 
clinical examination for visible signs, it is often unsuccessful at detecting asymptomatic 
infections. Fortunately, this study identified a low number of asymptomatic infections and 
none was primarily gonococcal or chlamydial infection, as usually reported (7).
Studies from sub-Saharan Africa indicate that VD syndrome is not helpful in the differential 
diagnosis of genital infections (8) and represents only a modest predictor of genital tract 
inflammation (9). Our stratification by cotrimoxazole prophylaxis use did not yield any 
difference in the prevalence of STIs or syndromes, especially VD. The study also suggests 
that syndromic management of genital infections in HIV care settings in Kenya would 
identify and treat around 47.6% and 55.4% of symptomatic, curable, episodes of VD and 
GUD, respectively, but would over treat an important number of women without indication 
for treatment.
The performance of KSD or SCD in predicting actual infections among symptomatic 
women was modest indicating that syndromic diagnosis may not be effective for screening 
genital infections in this population of HIV-infected women. An extensive review conducted 
by Pettifor et al. documented the ineffectiveness of syndromic management to treat genital 
infections in low-risk populations of women (10). Our findings are consistent with the 
review and highlight the urgent need for development of affordable and rapid diagnosis.
This study has some limitations. Because of the low number of bacterial infections such as 
gonorrhea and chlamydia, we were unable to assess co-factors associated with symptomatic, 
laboratory-confirmed genital infections. Because the gold standard for LAP diagnosis is not 
laboratory-centered, we were not able to validate the performance of syndromic diagnosis 
for LAP.
While annual laboratory-based screening for trichomoniasis among HIV-infected women 
has been recommended in a few studies (4, 11), aggressive partner notification and 
management should be equally sought. Growing evidence indicates genital microbiota is 
shared between sexual partners (12) and trichomoniasis prevalence may rise up to 73% 
among male partners of women diagnosed with vaginal trichomoniasis (13). Furthermore, 
up to 77% of trichomoniasis are asymptomatic in men (14) and may represent critical 
sources of infection and re-infections in women.
Given the relatively high study prevalence of vaginal infections such as BV, it is important 
to emphasize approaches to increase women’s awareness of urogenital symptoms with 
health care providers’ pro-active inquiry of genital symptoms and treatment (15). A recent 
study found an association between BV and increased risk of HIV-1 transmission to male 
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partners (15). Furthermore, BV recurs after treatment in 20%–30% of women within 3 
months (16) and in 75% of women with symptomatic and asymptomatic BV within 2 
months of treatment (17). Because of the high recurrence of BV and the potential ongoing 
risk of HIV transmission to male partners, approaches such as presumptive treatment may be 
warranted to promote healthy lactobacilli-dominant vaginal flora (18, 19) and to suppress 
inflammatory immune activation associated with the risk of HIV transmission and 
acquisition (20, 21). Research is needed to increase understanding of BV and to promote 
development of new therapies that maintain a sustained lactobacilli-dominant flora in the 
vagina. Because it is important to screen for STIs in HIV care programs, given the poor 
performance of syndromic management, it is essential develop better tools for laboratory 
diagnosis of STIs and genital infections in resource-constrained settings”.
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Summary
Women attending HIV care programs in Kenya have high rates of vaginal infections. 
Syndromic diagnosis was a poor tool in predicting these infections.
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